Pacira BioSciences Statistics
Total Valuation
PCRX has a market cap or net worth of $1.21 billion. The enterprise value is $1.52 billion.
| Market Cap | 1.21B |
| Enterprise Value | 1.52B |
Important Dates
The next estimated earnings date is Wednesday, May 1, 2024, before market open.
| Earnings Date | May 1, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
PCRX has 46.50 million shares outstanding. The number of shares has increased by 11.69% in one year.
| Shares Outstanding | 46.50M |
| Shares Change (YoY) | +11.69% |
| Shares Change (QoQ) | -0.17% |
| Owned by Insiders (%) | 1.21% |
| Owned by Institutions (%) | 108.23% |
| Float | 46.02M |
Valuation Ratios
The trailing PE ratio is 29.33 and the forward PE ratio is 9.10. PCRX's PEG ratio is -3.83.
| PE Ratio | 29.33 |
| Forward PE | 9.10 |
| PS Ratio | 1.80 |
| Forward PS | 1.72 |
| PB Ratio | 1.39 |
| P/FCF Ratio | 8.70 |
| PEG Ratio | -3.83 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.65, with an EV/FCF ratio of 10.91.
| EV / Earnings | 36.26 |
| EV / Sales | 2.25 |
| EV / EBITDA | 9.65 |
| EV / EBIT | 18.55 |
| EV / FCF | 10.91 |
Financial Position
The company has a current ratio of 5.24, with a Debt / Equity ratio of 0.67.
| Current Ratio | 5.24 |
| Quick Ratio | 3.94 |
| Debt / Equity | 0.67 |
| Debt / EBITDA | 3.72 |
| Debt / FCF | 4.20 |
| Interest Coverage | 4.04 |
Financial Efficiency
Return on equity (ROE) is 5.10% and return on invested capital (ROIC) is 4.09%.
| Return on Equity (ROE) | 5.10% |
| Return on Assets (ROA) | 2.70% |
| Return on Capital (ROIC) | 4.09% |
| Revenue Per Employee | $948,003 |
| Profits Per Employee | $58,926 |
| Employee Count | 712 |
| Asset Turnover | 0.44 |
| Inventory Turnover | 1.84 |
Taxes
In the past 12 months, PCRX has paid $19.75 million in taxes.
| Income Tax | 19.75M |
| Effective Tax Rate | 32.00% |
Stock Price Statistics
The stock price has decreased by -39.96% in the last 52 weeks. The beta is 0.75, so PCRX's price volatility has been lower than the market average.
| Beta (1Y) | 0.75 |
| 52-Week Price Change | -39.96% |
| 50-Day Moving Average | 29.05 |
| 200-Day Moving Average | 31.68 |
| Relative Strength Index (RSI) | 30.64 |
| Average Volume (30 Days) | 491,308 |
Short Selling Information
The latest short interest is 3.74 million, so 8.03% of the outstanding shares have been sold short.
| Short Interest | 3.74M |
| Short Previous Month | 4.07M |
| Short % of Shares Out | 8.03% |
| Short % of Float | 8.12% |
| Short Ratio (days to cover) | 7.15 |
Income Statement
In the last 12 months, PCRX had revenue of $674.98 million and earned $41.96 million in profits. Earnings per share was $0.89.
| Revenue | 674.98M |
| Gross Profit | 490.31M |
| Operating Income | 87.68M |
| Pretax Income | 61.70M |
| Net Income | 41.96M |
| EBITDA | 157.58M |
| EBIT | 82.01M |
| Earnings Per Share (EPS) | $0.89 |
Balance Sheet
The company has $278.58 million in cash and $586.04 million in debt, giving a net cash position of -$307.46 million or -$6.61 per share.
| Cash & Cash Equivalents | 278.58M |
| Total Debt | 586.04M |
| Net Cash | -307.46M |
| Net Cash Per Share | -$6.61 |
| Equity / Book Value | 870.13M |
| Book Value Per Share | 18.71 |
| Working Capital | 412.61M |
Cash Flow
In the last 12 months, operating cash flow was $154.65 million and capital expenditures -$15.16 million, giving a free cash flow of $139.49 million.
| Operating Cash Flow | 154.65M |
| Capital Expenditures | -15.16M |
| Free Cash Flow | 139.49M |
| FCF Per Share | $3.02 |
Margins
Gross margin is 72.64%, with operating and profit margins of 12.99% and 6.22%.
| Gross Margin | 72.64% |
| Operating Margin | 12.99% |
| Pretax Margin | 9.14% |
| Profit Margin | 6.22% |
| EBITDA Margin | 23.35% |
| EBIT Margin | 12.15% |
| FCF Margin | 20.67% |
Dividends & Yields
PCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.69% |
| Shareholder Yield | -11.69% |
| Earnings Yield | 3.46% |
| FCF Yield | 11.49% |
Analyst Forecast
The average price target for PCRX is $49.50, which is 89.66% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $49.50 |
| Price Target Difference | 89.66% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 10.86% |
| EPS Growth Forecast (5Y) | 42.13% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PCRX has an Altman Z-Score of 1.85 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.85 |
| Piotroski F-Score | 8 |